KORU Medical Systems Announces Subcutaneous Immunoglobulin Prefilled Syringe Development Agreement
25 January 2023 - 11:01PM
Business Wire
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU
Medical”), a leading medical technology company focused on the
development, manufacturing, and commercialization of innovative and
easy-to-use subcutaneous drug delivery systems that improve quality
of life for patients, today announced a development agreement with
a pharmaceutical manufacturer of subcutaneous immunoglobulin
therapy (SCIg) to develop and seek regulatory approval of the
Freedom Infusion System with an SCIg prefilled syringe.
“As KORU Medical looks to simplify subcutaneous drug delivery
for patients in the home, we are excited to partner with another
major pharmaceutical company to further innovate our Freedom
Infusion System™ for use with their prefilled syringes. Patients
prefer prefilled syringes as they simplify the challenging task of
transferring medication from vials,” said Linda Tharby, KORU
Medical’s President and CEO. “The Freedom Infusion System is the
only infusion system approved for prefilled syringes, and we are
excited by the opportunity to expand the number of prefilled
subcutaneous therapies that are FDA approved for our innovative
infusion system.”
The agreement provides for KORU Medical to develop an adaptation
to its Freedom Infusion System to enable an SCIg prefilled syringe
to be usable by patients globally and seek regulatory authorization
for adaptation. Terms of the agreement were not disclosed.
About KORU Medical
KORU Medical Systems develops, manufactures, and commercializes
innovative and easy-to-use subcutaneous drug delivery systems that
improve quality of life for patients around the world. The FREEDOM
Infusion System currently includes the FREEDOM60® and FreedomEdge®
Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo
Subcutaneous Safety Needle Sets™. These devices are used for
infusions administered in the home and alternate care settings. For
more information, please visit www.korumedical.com.
Forward-looking Statements
This press release contains forward-looking statements that
involve risks and uncertainties. Forward-looking statements can be
identified by words such as "will" and “seek” and include without
limitation the success and potential benefits of the Freedom System
adaptation. Actual results may differ materially from the results
predicted. The potential risks and uncertainties that could cause
actual results to differ from the results predicted include, among
others, whether KORU Medical can successfully develop and obtain
regulatory approval for the adaptation and those risks and
uncertainties included under the captions "Risk Factors" in our
Annual Report on Form 10-K for the year ended December 31, 2021,
which is available on the SEC website at www.sec.gov and on our
website at www.korumedical.com/investors. All information provided
in this release and in the attachments is as of January 25, 2023
and based on information available to us on the date hereof. We
undertake no duty to update this information unless required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230125005261/en/
Investor Contact: Greg Chodaczek 347-620-7010
investor@korumedical.com
KORU Medical Systems (NASDAQ:KRMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
KORU Medical Systems (NASDAQ:KRMD)
Historical Stock Chart
From Apr 2023 to Apr 2024